<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Schutt SD</submitter><funding>NIAID NIH HHS</funding><funding>National Institutes of Health, National Institute of Allergy and Infectious Diseases, National Institute of Allergy and Infectious Diseases</funding><pagination>e143950</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9621143</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>132(21)</volume><pubmed_abstract>Graft-versus-host disease (GVHD), manifesting as either acute (aGVHD) or chronic (cGVHD), presents significant life-threatening complications following allogeneic hematopoietic cell transplantation. Here, we investigated Friend virus leukemia integration 1 (Fli-1) in GVHD pathogenesis and validated Fli-1 as a therapeutic target. Using genetic approaches, we found that Fli-1 dynamically regulated different T cell subsets in allogeneic responses and pathogenicity in the development of aGVHD and cGVHD. Compared with homozygous Fli1-deficient or WT T cells, heterozygous Fli1-deficient T cells induced the mildest GVHD, as evidenced by the lowest Th1 and Th17 cell differentiation. Single-cell RNA-Seq analysis revealed that Fli-1 differentially regulated CD4+ and CD8+ T cell responses. Fli-1 prom</pubmed_abstract><journal>The Journal of clinical investigation</journal><pubmed_title>The druggable transcription factor Fli-1 regulates T cell immunity and tolerance in graft-versus-host disease.</pubmed_title><pmcid>PMC9621143</pmcid><funding_grant_id>R01 Al118305,R01 HL140953</funding_grant_id><funding_grant_id>R01 AI148403</funding_grant_id><pubmed_authors>Ben-David Y</pubmed_authors><pubmed_authors>Mealer C</pubmed_authors><pubmed_authors>McDaniel Mims B</pubmed_authors><pubmed_authors>Choi HJ</pubmed_authors><pubmed_authors>Cui W</pubmed_authors><pubmed_authors>Kharel A</pubmed_authors><pubmed_authors>Helke K</pubmed_authors><pubmed_authors>Hanief Sofi M</pubmed_authors><pubmed_authors>Bastian D</pubmed_authors><pubmed_authors>Nguyen H</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Liu C</pubmed_authors><pubmed_authors>Yu XZ</pubmed_authors><pubmed_authors>Wu Y</pubmed_authors><pubmed_authors>Schutt SD</pubmed_authors></additional><is_claimable>false</is_claimable><name>The druggable transcription factor Fli-1 regulates T cell immunity and tolerance in graft-versus-host disease.</name><description>Graft-versus-host disease (GVHD), manifesting as either acute (aGVHD) or chronic (cGVHD), presents significant life-threatening complications following allogeneic hematopoietic cell transplantation. Here, we investigated Friend virus leukemia integration 1 (Fli-1) in GVHD pathogenesis and validated Fli-1 as a therapeutic target. Using genetic approaches, we found that Fli-1 dynamically regulated different T cell subsets in allogeneic responses and pathogenicity in the development of aGVHD and cGVHD. Compared with homozygous Fli1-deficient or WT T cells, heterozygous Fli1-deficient T cells induced the mildest GVHD, as evidenced by the lowest Th1 and Th17 cell differentiation. Single-cell RNA-Seq analysis revealed that Fli-1 differentially regulated CD4+ and CD8+ T cell responses. Fli-1 prom</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2025-04-26T20:46:47.989Z</modification><creation>2025-04-06T16:31:56.78Z</creation></dates><accession>S-EPMC9621143</accession><cross_references><pubmed>36074578</pubmed><doi>10.1172/JCI143950</doi></cross_references></HashMap>